Early trial tests if lowering insulin can shrink fatty liver
NCT ID NCT07403604
Summary
This early-stage study aims to understand if lowering high insulin levels for one week can reduce the liver's production of new fat, a key driver of fatty liver disease. Researchers will compare a drug called diazoxide against a placebo in 25 adults with obesity, insulin resistance, and a fatty liver. The main goal is to gather knowledge about the disease process, not to treat participants' conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.